FDA advances peptide push to White House

The FDA submitted a peptide 'interim access policy' to the White House for review this week, according to a government filing. The policy would reportedly allow compounding pharmacies to temporarily produce and sell previously restricted peptides. The move advances an initiative championed by RFK Jr., who has pushed to broaden access to these treatments.